High-grade Glioma Clinical Trial
Official title:
Nurse-led Family and Network Consultations - Addressing Cancer-Related Symptoms and Concerns in Patients With High-grade Glioma and Their Families and Network (CARES)
Patients diagnosed with high-grade gliomas (HGG) experience a complex symptom burden including high-levels concerns. As a consequence to this life-threatening disease, the rely on close contact with a specialized neuro-oncological team as well as support and practical assistance from their families. However, multidimensional burden of caregivers has been reported. CARES seeks to facilitate and activate the existing resources within the patient and the network using a new model of systematic family care approach. Specialized neuro-oncological nurses are responsible for an expanded area providing an opportunity for the nursing profession to establish a new model of nursing care. This may not only benefit the patients and their families but also contribute to strengthen the nurses' professional identity and support further development of neuro-oncological specialist team.
Objectives To explore the feasibility and benefits of a 'Nurse-led Family and Network Consultation' (FNC) that seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side. To explore the impact of these nurse consultations on the nurses' perception of autonomy, self-esteem, and confidence, representing their professional identity. Methods This is a feasibility study in two parts: 1) a sample of patients with HGG (n=30) and their caregivers (n=30) recruited for informing the study about the family function, support and caregiver burden and 2) a sample of patients with HGG (n=30) and their caregivers (n=30) recruited for intervention group (IG) with 'Nurse-led Family and Network Consultations' using pretest and posttest measures. Part two applies a Mixed Method convergent design with a QUAL + QUAN design. Nursing BA students at Metropolitan University College will carry out affiliated bachelor projects within CARES. Theoretical framework Biopsychosocial Model International Classification of Functioning, Disability and Health (ICF) Use of narratives within neuro-oncology Feedback models and goal setting Symptom management theory The integrated Framework of Family System Nursing; Calgary Model Model of levels of personal and professional change Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns. Measurements Test time points: Post 1. FNC (week 1-2), post FNC 2 (week 8-10) and post FNC 3 (week 28-30) and post the 4. FNC (week 50-52). Part 1, questionnaires for cohort patients (n=30) and caregivers: The Caregiver Burden Scale (only caregivers) Hospital Anxiety and Depression Scale (HADS),(only caregivers) The ICE Family Perceived Support Questionnaire (ICE-FPSQ) (caregiver and patient, individually) Psychometric development of the Iceland-Expressive Family Functioning Questionnaire (ICE-EFFQ) (caregiver and patient, individually) Part 2, questionnaires for IG patients (n=30): The M.D. Anderson Symptom Inventory-Brain Tumour Module (before FNC) HADS The Functional Assessment of Cancer Therapy-Brain (FACT-Br) ICE-FPSQ ICE-EFFQ Questionnaires for IG family members (n=30): The Caregiver Burden Scale HADS ICE-FPSQ ICE-EFFQ Material from the FNC Written resume of each consultation (n=120) Interviews: Semi-structured telephone interviews with IG patients (n=30) and IG family member (n=30) post FNC 2 and post FNC 4 Focus group interview with project nurses post FNC 5 (n= 5 nurses) Analysis The MDASI-BT, HADS, FACT-Br, the ICE-EFFQ, the ICE-FPSQ and Caregiver burden scale to be analysed separately. Thematic analyses of interviews, field notes and resume according to Braun and Clarke. The Mixed Methods analytic approach is interpretive integration, which merges, compares, contradicts and discusses the data sets in order to achieve analytic integration in meta-inference. Time schedule May 2017 - December 2017: The preparatory phase February 2018 -August 2019: Cohort data collection March 2018- July 2018: Education of the project nurses August 2018 - February 2020: Intervention (1-year intervention with 6 months recruitment) Clinical and research implications New model of care in expanded nurse-led consultations relying on FNC may be powerful way to facilitate strategies to improve symptom management, emotional well-being and reduce concerns among families. This study will take at neurosurgical department and oncological department at Copenhagen University Hospital, Rigshospitalet in cooperation with neuro-oncological specialist team. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02305056 -
Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)
|
Phase 1 | |
Not yet recruiting |
NCT06002711 -
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
|
||
Recruiting |
NCT04299191 -
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00548938 -
Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
|
Phase 2 | |
Recruiting |
NCT05610891 -
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
|
Phase 1 | |
Completed |
NCT01644773 -
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
|
Phase 1 | |
Recruiting |
NCT02239952 -
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)
|
N/A | |
Completed |
NCT00565721 -
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
|
Phase 2 | |
Recruiting |
NCT05929456 -
Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)
|
Phase 1 | |
Recruiting |
NCT04552756 -
Seizures During Radiotherapy for High-grade Gliomas
|
N/A | |
Not yet recruiting |
NCT04482933 -
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
|
Phase 2 | |
Terminated |
NCT04730349 -
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT05873946 -
Assessing the Effectiveness of 2D Non-Navigated Intraoperative Ultrasound in Glioma Surgery
|
||
Recruiting |
NCT02848794 -
Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06209567 -
A Study of 68Ga-PSMA-11 PET Scans in People With Brain Tumors
|
Early Phase 1 | |
Not yet recruiting |
NCT06201351 -
Study of Adaptive Radiotherapy for High-grade Glioma Based on Interfraction MRI
|
||
Recruiting |
NCT06118723 -
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
|
||
Completed |
NCT00624728 -
Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
|
Phase 1/Phase 2 | |
Terminated |
NCT04851834 -
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04908267 -
How the Precise Habitats Can Predict the IDH Mutation Status and Prognosis of the Patients With High-grade Gliomas
|